About Aldo-keto reductase family 1 member C3
Aldo-keto reductase family 1 member C3 (AKR1C3) is a protein
from Homo sapiens identified by UniProt accession
P42330, 323 residues long.
MolForge cross-references it against 0 known binders and
273 disease associations.
Target properties
| Protein name | Aldo-keto reductase family 1 member C3 |
| UniProt accession | P42330 |
| Gene | AKR1C3 |
| Organism | Homo sapiens |
| Length | 323 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (16)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (273)
Diseases linked to this target (Open Targets).
- testosterone measurement · score 0.36
- metabolite measurement · score 0.22
- lung adenocarcinoma · score 0.22
- cutaneous melanoma · score 0.18
- heel bone mineral density · score 0.18
- head and neck squamous cell carcinoma · score 0.17
- breast adenocarcinoma · score 0.15
- venous thromboembolism · score 0.13
- prostate carcinoma · score 0.12
- prostate cancer · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P42330-F1 | alphafold | PREDICTED | 96.56 | — |
Amino-acid sequence (323 residues)
MDSKHQCVKL NDGHFMPVLG FGTYAPPEVP RSKALEVTKL AIEAGFRHID SAHLYNNEEQ VGLAIRSKIA DGSVKREDIF YTSKLWSTFH RPELVRPALE NSLKKAQLDY VDLYLIHSPM SLKPGEELSP TDENGKVIFD IVDLCTTWEA MEKCKDAGLA KSIGVSNFNR RQLEMILNKP GLKYKPVCNQ VECHPYFNRS KLLDFCKSKD IVLVAYSALG SQRDKRWVDP NSPVLLEDPV LCALAKKHKR TPALIALRYQ LQRGVVVLAK SYNEQRIRQN VQVFEFQLTA EDMKAIDGLD RNLHYFNSDS FASHPNYPYS DEY
Explore Aldo-keto reductase family 1 member C3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets